



November 3, 2011

Margaret Hamburg, M.D., Commissioner
Food and Drug Administration
15B-31 Parklawn Building
5600 Fishers Lane
Rockville, Maryland 20857

Dear Dr. Hamburg,

The bipartisan, bicameral Congressional Medical Technology Caucus, and other members of Congress join together to express our concerns about regulatory issues facing the medical device industry. This is an industry that has become increasingly important as dramatic improvements over the last decade have revolutionized healthcare and improved the quality of life for millions of Americans.

We share your commitment to ensuring safe and effective medical devices are available to patients. However, we are very concerned about recent declines in FDA performance. Increased review times, inconsistent expectations, and poor communication from the FDA are causing a lack of confidence and instability in the industry.

From the President's own Jobs Council report released this month

"Today, however, our medical innovation ecosystem is in jeopardy. Investment in the life sciences area is declining at an alarming rate because of the escalating cost, time and risk of developing new drugs and devices. While many factors have contributed to this decline - including challenges around reimbursement and the general state of the economy - an important factor is the uncertain FDA regulatory environment. These concerns come at a time when Europe, China, and India continue to entice companies to take their medical research and development enterprises abroad, putting at risk our ability to keep private investment and jobs here at home."¹

Dissatisfaction with the approval process is no longer just anecdotal: data shows the average time to approve a 510(k) application has increased by 43% from the 2003-2007 period to 2010.² The average time to approve a PMA application has increased 75%.³ The total review times for both 510(k)s and PMAs are now actually longer than they were before the user fee program was instituted.⁴

¹ United States. President's Council on Jobs and Competitiveness. *Taking Action, Building Confidence: Five Common Sense Initiatives to Boost Jobs and Competitiveness*, interim report, P.29. 2011. Online.

² FDA data analyzed by the Boston Consulting Group, *Competitiveness and Regulation: The FDA and the Future of America's Biomedical Industry*, February, 2011.

³ Ibid.

⁴ Ibid.

It has also become significantly more costly to get new products approved. Companies spend an additional \$520,000 a month as they wait for FDA approval of a 510(k) product and \$740,000 each month for a PMA product.⁵ This is simply unsustainable.

Today, the United States accounts for 40 percent of the global medical technology market⁶ and the industry indirectly creates two million American jobs.⁷ Maintaining American leadership in this field is essential for jobs and for patients. Unless we make significant improvements to the predictability and transparency of the regulatory process, we will lose the industry, the jobs that go with it, and the innovation to transform our healthcare system.

We recognize the need to balance risk and benefit; we all share patient safety as our primary concern, but there must be a "least burdensome approach" to achieve this without crippling an industry. We urge you to make every possible improvement to cut down device approval time by:

- Recognizing and correcting the disparity between "FDA time" versus real time when tracking device approvals
- Considering potential benefits of harmonization with international testing standards
- Addressing the unintended consequences of the conflict of interest rules for advisory panels
- Creating a transparent tracking and review system for applications and clearance decisions


These are just some of the ways the FDA can improve the process.

We appreciate the FDA's efforts in developing an Innovation Agenda and we recognize these changes will not take place overnight. However, stakeholders from innovators and patients, to investors and physicians all note that if the FDA does not restore regulatory certainty, predictability, and transparency, investment in the industry will continue to decline and this uniquely American success story could disappear.

Sincerely,



Amy Klobuchar
United States Senator



Scott P. Brown
United States Senator



Anna G. Eshoo
Member of Congress



Erik Paulsen
Member of Congress

⁵ Makower, Josh, M.D., Meer, Abed, M.D., Denend, Lynn, November 2010. *FDA Impact on U.S. Medical Technology Innovation*, P. 28. <http://www.advaMed.org/NR/rdonlyres/040E6C33-380B-4F6B-AB58-9AB1C0A7A3CF/0/makowerreportfinal.pdf>

⁶ *Medical Technology Innovation Scorecard, the Race for Global Leadership*. PWC, January 2011, page 8.

⁷ *State Economic Impact of the Medical Technology Industry*. Report prepared for AdvaMed by The Lewin Group, Inc. 2007



Richard Lugar
United States Senator




Al Franken
United States Senator



Debbie Stabenow
United States Senator



Brian Bilbray
Member of Congress




Jay Inslee
Member of Congress




David Dreier
Member of Congress



Michael Honda
Member of Congress



Dan Burton
Member of Congress



Betty McCollum
Member of Congress



Marlin Stutzman
Member of Congress




Bob Filner
Member of Congress



Ken Calvert
Member of Congress



Jason Altmire
Member of Congress




Charles Bass
Member of Congress



Andre Carson
Member of Congress




Mary Bono Mack
Member of Congress



Susan Davis
Member of Congress



Michael Burgess
Member of Congress




Joe Donnelly
Member of Congress




Todd Young
Member of Congress



Pat Tiberi
Member of Congress



Michael Rogers
Member of Congress



Marsha Blackburn
Member of Congress




Jim Gerlach
Member of Congress



John Kline
Member of Congress



Michael R. Turner
Member of Congress



Charles Dent
Member of Congress



Cathy McMorris Rodgers
Member of Congress



Michele Bachmann
Member of Congress



Brett Guthrie
Member of Congress



Aaron Schock
Member of Congress



Glenn Thompson
Member of Congress




Ann Marie Buerkle
Member of Congress



Chris Gibson
Member of Congress



Bill Huizenga
Member of Congress



Patrick Meehan
Member of Congress



Todd Rokita
Member of Congress

cc: Kathleen Sebelius, Secretary of Health and Human Services